H.C. Wainwright confident Spectrum BLA will be accepted and approved

After Spectrum Pharmaceuticals announced that it has submitted its Biologics License Application, or BLA, to the FDA for Rolontis, H.C. Wainwright analyst Edward White noted that the company had previously said it planned for a BLA filing by year end. White has confidence the BLA will be accepted and approved, pointing to the strength of the data and the fact it was conducted under a SPA, he tells investors. White keeps a Buy rating and $40 price target on Spectrum shares.
https://thefly.com/landingPageNews.php?id=2841541